BACE1

BACE1

B-site amyloid precursor protein (APP) cleaving enzyme. An aspartic-acid protease encoded by BACE1 on chromosome 11q23.2.-q23.3, which is linked to the pathogenesis of Alzheimer's disease and the formation of myelin sheaths in peripheral nerve cells. BACE1 is a transmembrane aspartic protease (beta-secretase) found in the Golgi apparatus, trans-Golgi network, secretory vesicles, and endosomes. It cleaves amyloid precursor protein (APP) in the brain into amyloid beta peptide, a major component of the amyloid plaques of Alzheimer's disease (AD), the deposition of which is the central pathology in AD, for which BACE1 is potential therapeutic target.
References in periodicals archive ?
BACE1 is transiently acetylated on lysine residues in the ER/ER-Golgi intermediate compartment.
reduction observed with MK-8931 may offer an opportunity to further understand the role BACE1 inhibition plays in the underlying pathology of Alzheimer's disease," said Darryle Schoepp, Ph.
Ginsenoside Rg1 attenuates beta-amyloid generation via suppressing PPARgamma-regulated BACE1 activity in N2a-APP695 cells.
In vitro, the allele blocked the effect of BACE1, reducing the production of Abeta42 by up to 50%.
This suggests that a well-tolerated BACE1 inhibitor might have a place in any future Alzheimer's treatment regimen.
Hypoxia-inducible factor 'alpha (HIF-1 alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation.
Reticulon family members modulate BACE1 activity and amyloid-[beta] peptide generation.
This is the first demonstration of the lowering of beta-amyloid levels by a BACE1 inhibitor in people with Alzheimer's disease," Forman said.
We observed an increase in ADAM10 and a decrease in BACE1 and APP695 protein levels and, subsequently, a reduction in A[beta] levels and A[beta] burden were present in HupA-treated mouse brain, suggesting that HupA enhances the nonamyloidogenic APP cleavage pathway.
Stefansson and his colleagues, it's easy to imagine how a new BACE1 inhibitor could be applied to a preclinical Alzheimer's population, with outcomes measured by the targets identified by Dr.
The study, performed in mice and utilizing post-mortem samples of brains from patients with Alzheimer's disease, identifies the complex mechanisms that result in a rapid and robust post-injury elevation of the enzyme, BACE1, in the brain.